TIPAT offers a state-of-the-art training program for 15 Early Stage Researchers (ESRs), who will study the translation and integration of biological and pharmacological data related to drug-drug interactions with pathogens towards personalized therapies. The TIPAT research and training programme will focus on combining state-of-the-art quantitative modelling with approaches in clinical pharmacology, immunology and microbiology to develop innovative methods for personalised antibiotic therapy.
The consortium consists of an interdisciplinary team of leading academic experts and cross-industry partners, including SMEs, pharmaceutical companies and hospitals. The TIPAT program is enriched by transferable regulatory and business skills training, which is delivered through thematically focused summer and winter courses.

The TIPAT network will also provide external stakeholders with the specialists trained through the program. The TIPAT training is thus expected to greatly enhance the career prospects of ESRs in universities, hospitals, industry or regulatory authorities, helping them to develop scientific innovations, provide the optimal therapy for individual patients and thus make an important contribution to the fight against antibiotic resistance.

The project is funded with approximately 4 million euros within the EU's HORIZON2020 initiative (H2020-EU.1.3.1.).

Funding period:
01 March 2020 - 29 February 2024

Further information about the ITN - TIPAT